ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.

NCT00440479 · clinicaltrials.gov ↗

COMPLETED

Status

11

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma
Hematological Neoplasms

Interventions

DRUG: Bortezomib

Sponsor

Janssen-Cilag B.V.